Skip to main content
. 2020 Jun 16;51(7):2066–2075. doi: 10.1161/STROKEAHA.120.028825

Figure 3.

Figure 3.

Cumulative incidence curves for the evaluation of risk of stroke and systemic thromboembolic events (effectiveness) outcomes during the overall follow-up period. VKA indicates vitamin K antagonist.